The Medicines Company looks strong ahead of the FDA decisions later this month $MDCO

The Medicines Company ($MDCO) recently reported its second quarter results as the company also provided details about its corporate developments. The Medicines Company’s global net revenue stood at $18.7 million, in comparison to $54.7 million it had reported for the second quarter of the previous year. The company’s net loss [...]

By |August 24th, 2017|Monthly Investment Ideas|0 Comments

Intersect posts strong Q2 numbers, looks forward to FDA ruling for Sinuvatm ($XENT)

Intersect ENT Inc. ($XENT) specializes in Ear, Nose and Throat segment where it develops and markets novel drugs devices. It focuses on providing innovating implants for treating various conditions related to ear, nose and throat. The company recently reported its second quarter results where its revenue stood at $24 million, [...]

By |August 22nd, 2017|Monthly Investment Ideas|0 Comments

Clovis stock looks promising with strong Rubraca sales numbers $CLVS

Clovis Oncology Inc. ($CLVS) recently announced its second quarter financial results. The company also provided updates about its lead product Rubraca, which was launched in December, 2016. Clovis reported net product revenue for the drug at $14.6 million for the quarter, up from $7 million it had announced for the [...]

By |August 17th, 2017|Monthly Investment Ideas|0 Comments

Verastem stock to retain momentum with strong trial data $VSTM

Verastem Inc. ($VSTM) stock showed impressive performance this year by registering over 177 growth. The company recently reported its second quarter results with its net loss for the period at $13.4 million, up from a net loss of $8.6 million for the corresponding quarter of the previous year. However, the [...]

By |August 15th, 2017|Monthly Investment Ideas|0 Comments

The Medicines Company stock set to benefit from strong quarterly numbers $MDCO

The Medicines Company ($MDCO) stock showed positive reaction to its second quarter earnings announcement. The company reported its global revenue for the quarter at $18.7 million. The revenue figure included $10.7 million as aggregate revenue from Angiomax. Minocin and Orbactive recorded aggregate sales of $8.0 million in the second quarter [...]

By |August 10th, 2017|Monthly Investment Ideas|0 Comments

Aclaris files Marketing Authorization Application in EU, creating a new stock catalyst $ACRS

Aclaris Therapeutics ($ACRS) stock presents a strong investment opportunity as the company is awaiting the FDA approval for its Seborrheic Keratosis treatment. Its lead drug candidate A-101 is a strong contender to become the first FDA approved treatment for the condition. The company has already received a Notice of Allowance [...]

By |August 8th, 2017|Monthly Investment Ideas|0 Comments

Ultragenyx Pharmaceuticals stock to benefit from better than expected quarterly numbers $RARE

Ultragenyx Pharmaceuticals Inc. ($RARE) announced its better than expected quarterly results, providing a further fillip to its stock price. The stock is currently nearly 30 percent below its 52 weeks high of $91.35 and is in recovery mode. The positive quarterly earnings and its robust pipeline are expected to fuel [...]

By |August 3rd, 2017|Monthly Investment Ideas|0 Comments

Neurocrine Biosciences a strong buy ahead of earnings announcement $NBIX

Neurocrine Biosciences Inc. ($NBIX) is set to announce its second quarter earnings on August 3rd. The company is expected to provide update about its recently approved Ingrezza capsules. This is the first FDA approved therapy for treating Tardive Dyskinsia (TD). The company had reported a net loss of $0.90 per [...]

By |August 1st, 2017|Monthly Investment Ideas|0 Comments

Rigel Pharmaceuticals looks strong ahead of FDA decision for Tavalisse

Rigel Pharmaceuticals Inc. ($RIGL) stock is currently trading over 43 percent lower than its 52 weeks high of $4.38, showing a steep upside potential ahead. The company stock is likely to get boost from its progress on fostamatinib, an oral spleen tyrosine kinase inhibitor, for the treatment of patients with [...]

By |July 27th, 2017|Monthly Investment Ideas|0 Comments

Enanta stock to gain from upcoming FDA decision for HCV drug $ENTA

Enanta Pharmaceuticals ($ENTA) focuses on developing therapies for liver conditions. The company has a strong Hepatitis C virus (HCV) portfolio, which it continually expands. Apart from HCV, the company also focuses on other liver related ailments such as Respiratory Syncytial Virus infection (RSV) and Non-alcoholic Steatohepatitis (NASH). However, the upcoming [...]

By |July 25th, 2017|Monthly Investment Ideas|0 Comments

Kamada stock set to recover from EMA withdrawal shock, presents good investment opportunity $KMDA

Kamada Ltd. ($KMDA) stock showed strong performance as it gained over 42 percent in the past 12 months. However, the actual performance of the stock was overshadowed by a steep decline of 25 percent in the past one month. The decline was mainly due to the company’s withdrawal of European [...]

By |July 20th, 2017|Monthly Investment Ideas|0 Comments

Valeant sells off business unit to reduce debt pile, pushing stock higher $VRX

Valeant Pharmaceuticals International Inc. ($VRX) stock gained over 19 percent this year so far. After a prolonged period of downward spiral, the stock is showing signs of revival. The change is mainly on account of the company taking strategic decision to boost its core business and trim its debt pile. [...]

By |July 18th, 2017|Monthly Investment Ideas|0 Comments

Tesaro stock to gain from first mover PARP inhibitors ovarian cancer drug $TSRO

Tesaro Inc. ($TSRO) stock has gained over 55 percent in the past 12 months. The stock price has kept up with the operational success of the company as Tesaro received significant drug approvals in the US and Europe. The stock is also expected to keep up the momentum as the [...]

By |July 13th, 2017|Monthly Investment Ideas|0 Comments

AcelRx banks on DSUVIA, offers robust short term investment opportunity

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX), after suffering a setback with its Zalviso drug, is looking to hear some positive news. AcelRx is scheduled to announce its Phase 3 study data later this month. The company had received the CRL pertaining the drug in July, 2014. The CRL asked the company to [...]

By |July 11th, 2017|Monthly Investment Ideas|0 Comments

Premarket Biotech Digest – $CELG inks new deal, $LLY gets favorable ruling, $ALR modifies deal

Celgene Corporation ($CELG) announced that it has agreed to acquire a stake in BeiGene. The deal has valued BeiGene stock at $4.58 apiece. The company will buy 5.9 percent of the total stock, which would be 32.7 million shares. BeiGene is set to receive [...]

By |July 10th, 2017|Monthly Investment Ideas|0 Comments

Ocular stock looks solid ahead of a key FDA decision $OCUL

Ocular Therapeutix Inc. ($OCUL) is a biopharmaceutical company and focuses on developing treatments for ocular conditions using its hydrogel platform technology. The company is currently on the verge of a major catalyst as it awaits the FDA decision for its Dextenza treatment due on July 19th, which is its lead [...]

By |July 7th, 2017|Monthly Investment Ideas|1 Comment

Anika Therapeutics offers a long term growth opportunity with robust pipeline $ANIK

Anika Therapeutics Inc. ($ANIK) is an orthopedic medicines company and it employs its hyaluronic acid (HA) technology for developing various treatments. The company offers a good potential for medium to long term investment as it has a strong and diversified product pipeline. Apart from the pipeline, it also has robust [...]

By |July 5th, 2017|Monthly Investment Ideas|0 Comments

Pacific Biosciences looks promising as it targets low competition plant genome segment $PACB

Pacific Biosciences of California Inc. ($PACB) is engaged in developing and manufacturing sequencing systems for solving genetic issues. The company recently developed a new sequencing system for the maize genome, which is expected to pave the way for complex crop as well as livestock genomes. The company used its proprietary [...]

By |June 29th, 2017|Monthly Investment Ideas|0 Comments

Omeros Corporation: Multiple drug candidates make for attractive long term investment $OMER

Omeros Corporation ($OMER) is a biopharma company which is engaged in developing small molecule and protein therapeutics for different conditions. The company emerges as a strong investment target with its diverse drug pipeline. Once the company’s strong performance in these trials is factored in, the stock becomes even more attractive [...]

By |June 27th, 2017|Monthly Investment Ideas|0 Comments

Corbus moves lead candidate to Phase 3 study, offers good investment deal $CRBP

Corbus Pharmaceuticals Holdings ($CRBP) is engaged in controversial yet lucrative medical cannabis sector. The company is currently working to develop  anabasum, an endocannabinoid-mimetic drug to treat inflammatory and fibrotic diseases. It recently announced the results from the previously completed Phase 2 clinical study of the lead drug candidate for the [...]

By |June 22nd, 2017|Monthly Investment Ideas|0 Comments
s2Member®